News and Announcements
AI Health-tech VivoDoc has already secured nationwide clientele and investment from within the medical community
- Published May 05, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“At VivoDoc we understand health is a blessing. Everyone deserves the right care at the right time. We are here to guide you all through the healthcare journey and care for you when you need it the most.
Myself being a physician, I worked in major healthcare systems and there is dire need for a unique comprehensive healthcare platform. I cofounded VivoDoc, where we strive to make healthcare affordable, accessible and easy for patients, simultaneously providing our physicians with modern technology and all in one platform to run a successful practice.
We provide convenience along with saving precious time to prevent physician burnout”.
Dr Rahman Mohammed, CEO and Cofounder, VivoDoc
Executive Summary
VivoDoc is a health-tech venture striving to bring in price transparency and ease of scheduling appointments for patients. VivoDoc equips healthcare providers and patients with tools created using AI & ML to discover the right type of care and drive optimal outcomes for their medical conditions by managing the patient care journey.
Investment Highlights
- Digitally native company founded by physicians for physicians.
- Market size of $74B USD with 38% CAGR in next 5 years.
- Current investors are physicians who are end users of the platform.
- VivoDoc has already secured key clients including independent healthcare providers such as dentists and other specialists nationwide.
- Partnered with Epic for EMR Integration; Infermedica for real-time patient self-triage functionality; and Change Healthcare and pVerify for eligibility checks.
Investment Offering
VivoDoc is raising $2.5M for 25% equity to fund their marketing campaign, expand the product range and grow partnerships.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
